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Many patients with postural tachycardia syndrome (PoTS) suffer from fatigue, daytime
sleepiness, and sleeping disturbances.The objective of this study was to compare subjec-
tive and objective sleep quality of PoTS patients with a group of healthy controls. All patients
completed a Pittsburgh Sleep Quality Index questionnaire and the Epworth Sleepiness
Scale. The patients sleep architecture, heart rate, and heart rate variability (HRV) measure-
ments were taken during one night at the sleep laboratorium. All data was collected at
the Sleep Unit, at Helios Klinikum Wuppertal. Thirty-eight patients diagnosed with PoTS
were compared to 31 healthy controls, matched in age and gender. Patients with PoTS
reached significantly higher scores in sleep questionnaires, which means that they were
more sleepy and had a lower sleep quality. Polysomnography showed a significantly higher
proportion of stage 2 sleep.The results of HRV analysis in different sleep stages confirmed
changes in autonomic activity in both groups. PoTS patients, however, showed a dimin-
ished variability of the low-frequency (LF) band, high-frequency (HF) band, and LF/HF ratio
in different sleep stages. It can therefore be gathered that PoTS could be considered as
potential differential diagnosis for sleep disturbances since PoTS patients had a subjective
diminished sleep quality, reached higher levels of daytime sleepiness, and showed a higher
proportion of stage 2 sleep. PoTS patients showed furthermore a reduction of LF/HF ratio
variability in different sleep stages.
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INTRODUCTION
The postural tachycardia syndrome (PoTS) is characterized by
symptoms of orthostatic intolerance and an excessive increase
in heart rate (by ≥30 or to ≥120 bpm) when upright (1–3).
Typical complaints of the otherwise healthy patients are palpi-
tations, weakness, blurred vision, chest pain, sweating, dizziness,
presyncope, shortness of breath, tremulousness, fatigue, poor noc-
turnal sleep, and sleep dysfunction including waking up at night
repeatedly and night sweating (4). PoTS is a heterogeneous and
multifactorial disorder (5). PoTS manifests itself with symptoms of
cerebral hypoperfusion and excessive sympathoexcitation but the
exact pathophysiology remains as of yet unknown. It has however
been found that the pathophysiology of PoTS includes impaired
sympathetically mediated vasoconstriction, excessive sympathetic
drive, volume dysregulation, and deconditioning, which can all be
variously combined.
As mentioned before, some of the chief complaints of PoTS
patients are increased daytime sleepiness, fatigue, and diminished
quality of night time sleep. In 1921, Swan et al. already mentioned
sleep disturbances in relation to PoTS-like symptoms (6). Also
Craig et al. and Wood et al. mentioned the incidence of sleep dis-
turbances in their publications regarding neurocirculatory asthe-
nia, which is consistent with today’s definition of PoTS (7, 8).
Recent studies confirmed this coherency. In 2007, Thieben et al.
investigated 152 medical records which showed that 31.6% of PoTS
patients had sleep disturbances and even 48% had severe fatigue
(4). Bagai et al. discovered significantly more severe sleep distur-
bances, higher fatigue levels, and excessive daytime sleepiness in a
group of 44 PoTS patients compared to normal controls (n= 46)
using questionnaires (9). All published evidence is focused on the
subjective sleep quality of PoTS patients or actigraphy (10). As of
yet, there is no published data regarding objective sleep evaluation
of PoTS patients with a polysomnographic (PSG) examination of
their sleep quality. The aim of this study is therefore to evaluate
subjective and objective sleep quality of PoTS patients compared
to a group of healthy controls matched in age and gender. As
both sleep and PoTS may be affected by the regulation of the auto-
nomic nervous system (ANS), it can be assumed, that a connection
between autonomic dysfunction and sleep disturbance exists. To
evaluate this putative coherency, heart rate variability (HRV) was
used as an objective measurement for the ANS.
MATERIALS AND METHODS
The present clinical trial is a prospective competitive study of
patients and controls who presented to the Department of Neurol-
ogy and Neurophysiology, Helios Klinikum Wuppertal in between
June 2010 and September 2011. PoTS patients were mainly exam-
ined during the course of their hospitalization. Control subjects
were recruited within private contacts and examinations were per-
formed as outpatients. Within the study, we examined 38 patients,
which fulfilled conventional criteria of PoTS and 31 healthy con-
trol subjects that did not show any symptoms of orthostatic
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intolerance. All participants completed an informed consent form
prior to taking part. Inclusion criteria for the PoTS group were
symptoms of orthostatic intolerance plus an increase in heart rate
by ≥30 or to ≥120 bpm during upright position. Excluding cri-
teria for both patient groups were all conditions that could affect
the autonomous nervous system, such as Parkinson’s disease, dia-
betes mellitus, alcoholism, hypertension, defects of the thyroid,
pheochromocytoma, anemia, dementia, multiple sclerosis, cardiac
arrhythmias, or polyneuropathy. Furthermore, patients with psy-
chiatric disorders were excluded. A constant medication or current
pregnancy was additional exclusion criterion.
AUTONOMIC TESTING
All participants underwent a 70°-tilt table study at the Autonomic
Laboratory at Helios Klinikum Wuppertal in order to assess their
orthostatic cardiovascular function. All subjects were examined
between 7.30 a.m. and 12.30 a.m. Time spent upright on the tilt
table varied between 10 and 45 min, depending on the patients
tolerance. During this procedure, blood pressure, heart rate, and
breathing rate were continuously monitored by a FAN™ computer
(Schwarzer, Heilbronn, Germany). Blood pressure was addition-
ally continuously measured with a Portapress device (TNO-TPD
Biomedical Instrumentation, Amsterdam, Netherlands) following
the method described by Penáz (11, 12). Each participant com-
pleted a Valsalva maneuver during which blood pressure and heart
rate were monitored. The maneuver was accomplished in supine
position (13). After a rest period of 1 min, each participant was
asked to expirate against a pressure of 20–40 mmHg for approx-
imately 15 s. Valsalva ratio and changes of blood pressure were
measured by the FAN™ device (Schwarzer GmbH, Munich, Ger-
many). The FAN™ device records HRV based on the standard
recording techniques and algorithms used in autonomic function
studies (14). The FAN™ has an interface box for the recording
of ECG, breathing frequency, and expiratory pressure, e.g., during
Valsalva maneuver. ECG and breathing frequency were digitized
with a sampling rate of 500 Hz; where the expiratory pressure
could be recorded with the limits of 0–100 mm mercury. The
interface also offers the opportunity to record one analog external
signal of blood pressure from an external monitor (digitizing rate
500 Hz).
POLYSOMNOGRAPHY
All participants were monitored in the Sleep Unit, Helios Klinikum
Wuppertal that fulfills the requirements by the German Society
of Sleep Science and Sleep Medicine (DGSM). As a standard
procedure, all patients stayed overnight and were attended with
PSG. The recordings were evaluated using “Alice 5” – PSG soft –
and hardware (Heinen & Loewenstein, Bad Ems, Germany). The
PSG recording included six channel electroencephalogram (EEG)
(including frontal, central, occipital bilateral referencing to right
and left mastoid), right and left electro-oculography, bilateral
surface EMG of mentalis and of right and left tibialis anterior mus-
cles, 2 channel ECG, oronasal thermistor, thoracic and abdominal
respirograms, absolute position transducer larynx microphone,
and oxygen saturation. The subjects reported to the sleep unit at
8.00 p.m. Monitoring was performed for at least 6 h (10 p.m. until
5 a.m.) All patients were monitored over the period of one night.
DATA ANALYSIS
Sleep data were staged visually according to the rules of Rechtschaf-
fen & Kales and furthermore according to the criteria of the
American Association of Sleep Medicine using 30 s time frames,
by two independent investigators (15, 16). PSG parameters like
mean heart rate in NREM and REM sleep, Total sleep time (TST),
total in bed time (TIBT), sleep efficiency (TST/TIBT), sleep onset
latency (minutes), REM latency (minutes), quantity of stage 2 (%),
slow wave sleep (%), and REM (%) sleep were analyzed. Arousals
were defined as abrupt changes in EEG pattern with return to
alpha or theta frequency, lasting between 3 and 10 s and were also
analyzed according to the criteria of the American Association of
Sleep Medicine (16).
HEART RATE VARIABILITY
Heart rate variability data were detected using ECG signals: 5 min
segments of artifact-free ECG data during sleep stage 2, slow wave
sleep, and REM sleep were selected for analyses (17). ECG lines
were extracted from Alice 5 software and transferred to the fan
computer by an ASCI file. All ECG lines were visually controlled
for artifacts and extra-systoles. HRV was automatically analyzed
with ASCI 2 at a sampling rate of 500 Hz by the Fan device soft-
ware according to the “Recommendations of the International
Federation of Clinical Physiology for the Practice of Clinical Neu-
rophysiology” (18, 19). In short, the ECG signal was digitized at a
sample rate of 500/s. Respiration was monitored by registration of
chest movements. A fast Fourier transform (FFT)-based algorithm
was used for the spectral analysis of HRV. The RR intervals were
converted to 4 Hz and an exact Hamming window was applied for
FFT. The power in frequency ranged from low frequencies (LF:
0.04–0.15 Hz) to high frequencies (HF: 0.15–0.40 Hz). Spectral
analysis allowed a differentiation of sympathetic and parasympa-
thetic activation, which were related to a LF and a HF component
of the HRV signal, respectively. LF band reflected a combination of
sympathetic and parasympathetic influences and baroreflex func-
tion. HF band reflected parasympathetic activity. The resulting
LF/HF ratio as a quantitative index of the sympathovagal balance
was calculated.
EPWORTH SLEEPINESS SCALE
The Epworth Sleepiness Scale (ESS) is a standardized question-
naire, which documents subjective daytime sleepiness. It is focused
on eight specific daily situations including sitting, reading, watch-
ing television, passive sitting (e.g., in a theater), co-driving, while
stopping and driving (e.g., on a traffic light), afternoon rest, sitting
while having a conversation and after lunch (without the con-
sumption of alcohol). Patients were asked to rank sleepiness in
these situations on a scale of 0–3 points. Total possible maximum
would have been 24 points. Prior studies showed that an ESS Score
over 10 is related to enhanced daytime sleepiness (20).
PITTSBURGH SLEEP QUALITY INDEX
The Pittsburgh Sleep Quality Index (PSQI) is a standardized
questionnaire to retrospectively document subjective sleep qual-
ity during the past for weeks (21). Its seven categories consist
of subjective sleep quality, sleeping time, sleep latency, intake of
sleep medication, sleep efficiency, sleep disturbances, and daytime
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sleepiness. Each category can score up to three points. Total maxi-
mum score would be 21 points. Participants could be classified in
three groups. A score of ≤5 indicates good quality of sleep, a score
≥5 and ≤10 indicated minor quality of sleep, and a score of ≥10
correlated with chronic sleeping disorders.
ETHICS OF INVESTIGATIONS
All clinical studies conformed with the principals of the declara-
tion of Helsinki. A positive voting of the Ethics committee of the
University of Witten/Herdecke had been obtained prior to data
collection.
STATISTICAL METHODS
All statistical analyses were performed using SPSS for Windows v.
20.0 (SPSS Inc., Chicago, IL, USA) with assistance of the statisti-
cian Dr. Lange. Descriptive statistics are presented as mean± SD or
median [plus interquartile range (>IQR)]. To compare indepen-
dent variables Mann–Whitney-U or Fisher Tests were performed.
For more than two dependant variables, Friedman test was used.
All tests were two-tailed. Statistical significance was set at p= 0.05.
RESULTS
DEMOGRAPHICS
Sixty-nine persons in total were examined, 38 patients with
PoTS, and 31 healthy controls. PoTS patients were predomi-
nantly female (74%). They were between 18 and 41 years of
age, with a mean age of 25.3± 7 years (females: 24.4± 6.2 years,
males: 27.8± 8.1 years). Age and gender of control subjects was
adapted to the PoTS group not resulting in significant differences
(age p= 0.183, gender p= 0.518). Thirty-one healthy participants
were assigned to the control group, 20 females (65%) and 11
males. The mean age of this group was 26.2± 6.3 years (females:
25.7± 5.8 years, males: 27.2± 7.5 years). Controls were recruited
within a university setting.
AUTONOMIC TESTING
Head-up tilt table testing showed an increase in heart rate of
PoTS patients with a median of 38.99 bpm (30.00–43.00). This
was significantly higher than in controls (p= 0.000), who showed
a median in heart rate increase by 15.00 bpm (12.00–25.00). No
significant changes in blood pressure were found in both groups.
During Valsalva maneuver, blood pressure was continuously mea-
sured. PoTS patients had an increase in systolic blood pressure
during phase 4 of the maneuver with a median of 27.00 (16.00–
44.00) mmHg. Controls, however, showed an increase systolic
pressure with a median of 21.00 (15.00–26.00) mmHg, resulting in
a statistically significant difference in between groups (p= 0.019).
PoTS patients showed furthermore significantly higher parameters
in the Valsalva ratio (1.92 vs. 1.75; p= 0.0036).
SUBJECTIVE SLEEP QUALITY AND SLEEPINESS
Twenty-five PoTS patients and 31 control subjects answered PSQI
and ESS questionnaires. The maximum PSQI score reached by
PoTS patients was 17, controls reached a maximum score of 12.
Ten PoTS patients accomplished a score≥10 (40%). Whereas only
one participant of the control group scored ≥10. Compared to
controls, PoTS patients reached a significantly higher score in PSQI
[PoTS in median: 8 (4–13); where controls had a median of 4 (3–5)
p= 0.01]. PoTS patients reach higher scores in ESS than controls,
but the median did not exceed the cut-off of 10 [PoTS in median:
6 (3–9); where Controls had a median of 3 (1–5) p= 0.01]. The
maximum score in the PoTS group was 17, participants in the con-
trol group reached a maximum score of 7. 24% of PoTS patients
reached a score over 10, while none of the control subjects did,
however, this did not reach statistic significance (p= 0.088).
POLYSOMNOGRAPHY
The mean heart rate during different sleep stages is shown in
Table 1. PoTS patients have a higher mean heart rate in both
sleep stages, NREM and REM, but there is no significant difference
between the two groups (Table 1). Parameters that describe the
sleep efficiency did not differ significantly in both groups (Table 2).
Both groups slept well, with a total sleeping time in median
of 359.00 (324.50–381.50) minutes (PoTS) and 350.00 (332.50–
375.50) minutes (controls) and sleep efficiencies in median of
96.03 (91.54–98.46)% (PoTS) and 95.56 (93.06–98.38)% (con-
trols). PoTS patients have a significantly higher percentage of stage
2 sleep than controls (42.45 vs. 36.70%; p= 0.017). They also show
a slightly lower proportion of slow wave sleep (39.25 vs. 41.30%).
PoTS patients show a higher proportion of REM sleep (15.10 vs.
12.90%). Furthermore, four of the PoTS patients did not even
reach REM sleep stage during the whole night.
AROUSALS
Arousals during night time sleep was measured and manually
assessed. It was defined as an increase in EEG frequency lasting
at least over a period of 3–10 s. In PoTS patients, there was a total
of 41.00 (33.00–50.00) arousals measured, while control subjects
showed only 37.00 (27.00–66.00; n.s.). Three of the PoTS patients
showed 15 or more periodic leg movements (PLM) per hour,which
is consistent with nocturnal movement disorder. One of the PoTS
patients showed an index as severe as 54/h. None of the control
subjects exhibited more than 11 PLM/h. Furthermore, one of the
PoTS patients was diagnosed with obstructive sleep apnea with
a REM-AHI of 41.5/h and AHI 10.5/h, showing a mean of nine
respiratory arousals per hour. In control subjects, no respiratory
arousals could be identified.
HEART RATE VARIABILITY
Low-frequency band
No significant difference in the LF band component between the
two groups was found (Table 3). There is no significant increase
or decrease of the LF band during different sleep stages in PoTS
Table 1 | Heart rate during NREM and REM sleep presented in median
with its interquartile range.
Variable PoTS Controls pValue
Mean heart
rate NREM
61.60 (56.10 – 68.00) 59.60 (54.90 – 68.90) 0.859
Mean heart
rate REM
66.75 (57.50 – 70.20) 63.20 (58.50 – 70.30) 0.864
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Table 2 | Parameters of sleep efficiency and sleep architecture presented in median with its interquartile range.
Variable PoTS Controls pValue
Total in bed time (TIBT) (minutes) 401.50 (385.00 – 423.00) 402.00 (386.00 – 423.00) 0.777
Sleep period time (SPT) (minutes) 372.00 (349.50 – 398.50) 368.50 (353.50 – 396.00) 0.847
Total sleep time (TST) (minutes) 359.00 (324.50 – 381.50) 350.00 (332.50 – 375.50) 0.828
Sleep efficiency (TST/SPT) (%) 96.03 (91.54 – 98.46) 95.56 (93.06 – 98.38) 0.981
TST/TIBT (%) 90.52 (82.95 – 93.78) 87.26 (84.54 – 91.72) 0.546
Sleep latency (minutes) 21.25 (16.50 – 29.00) 24.50 (17.00 – 38.00) 0.393
REM latency (minutes) 138.50 (64.00 – 192.50) 122.50 (84.50 – 227.50) 0.173
Sleep stage 2 (%) 42.45 (35.30 – 48.60) 36.70 (30.60 – 43.00) 0.017
Slow wave sleep (%) 39.25 (31.40 – 47.90) 41.30 (33.00 – 50.90) 0.337
REM (%) 15.10 (6.90 – 19.80) 12.90 (9.90 – 18.70) 0.537
Table 3 | LF band power (ms2/s) across different sleep stages in
median with its interquartile range.
Variables PoTS Controls pValue
Sleep
stage 2
336.68 (149.52 – 641.58) 498.09 (185.81 – 689.04) 0.392
Slow wave
sleep
224.69 (118.87 – 589.83) 227.18 (89.03 – 663.87) 0.968
REM 365.20 (155.00 – 591.14) 285.77 (165.65 – 562.34) 0.767
Table 4 | HF band power (ms2/s) across different sleep stages in
median with its interquartile range.
Variables PoTS Controls pValue
Sleep
stage 2
333.10 (188.72 – 600.79) 250.91 (155.79 – 969.79) 0.975
Slow wave
sleep
342.34 (181.68 – 621.52) 237.18 (166.18 – 678.45) 0.386
REM 227.39 (112.47 – 749.35) 176.39 (62.62 – 389.17) 0.192
patients, whereas individuals in the control group had a signifi-
cant decrease in sleep stage 2 to slow wave sleep (p= 0.014). In a
summary, these results showed a reduction of variability of the LF
band during different sleep stages in PoTS patients.
High-frequency band
There was no statistically significant difference between HF bands
in between PoTS patients and controls (Table 4). In controls, there
were significant differences of HF band between stage 2 and slow
wave sleep (p= 0.018) and stage 2 and REM (p= 0.006), but there
was no statistical difference between HF band of slow wave sleep
and REM. In PoTS patients, there was no statistical difference
of HF band increase or decrease between sleep stages 2, slow wave
sleep, and REM. HF band of PoTS patients did not vary in between
sleep stages as much as control subjects.
LF/HF RATIO
There was no statistically significant difference between the two
study groups (Table 5). PoTS patients showed a decrease of LF/HF
ratio from stage 2 to stage 4 (n.s.) and an increase to stage
Table 5 | LF/HF ratio across different sleep stages in median with its
interquartile range.
Variables PoTS Controls pValue
Sleep stage 2 0.82 (0.47 – 1.69) 0.93 (0.58 – 1.99) 0.542
Slow wave sleep 0.64 (0.36 – 1.41) 0.81 (0.46 – 2.21) 0.386
REM 1.14 (0.51 – 2.63) 1.52 (0.87 – 3.91) 0.187
REM (n.s.). In controls, there were significant changes in HRV in
between sleep stages. LF/HF ratio was higher in sleep stage 2 than
in slow wave sleep (p= 0.265), and in both stage 2 (p= 0.002)
and slow wave sleep (p= 0.002) were significantly lower com-
pared to REM sleep. PoTS patients show a reduction of LF/HF
ratio variability in different sleep stages.
DISCUSSION
In order to assess subjective and objective sleep quality of PoTS
patients, this study considered a group of 38 PoTS patients and
compared them to a group of 31 healthy controls matched in
age and gender. All patients included met standard diagnostic
criteria for PoTS. Basically, the results obtained in this study con-
firmed current literature, i.e., PoTS patients showed physiological
autonomic control of the baroreflex arc as shown by the Valsalva
maneuver with diminished subjective sleep quality and increased
daytime sleepiness. For the first time, it was demonstrated that in
PoTS patient the macrostructure of sleep is physiological by means
of PSG recording. Autonomic testing showed a significantly higher
Valsalva ratio in PoTS patients as compared to normal subjects.
This conforms to former studies of Sandroni et al. who found
a higher Valsalva ratio in PoTS patients and ascribed this to an
increased β-adrenergic tone (22). Furthermore, there was a higher
increase in systolic blood pressure in PoTS patients during Valsalva
maneuver compared to control subjects, which also reflected the
findings of Sandroni et al. (22). Forty percent of PoTS patients
in this study suffered from subjective diminished sleep quality
as evaluated by a standardized PSQI questionnaire. Furthermore,
24% reached an ESS score above 10, which reflected excessive
daytime sleepiness in those patients. Our study confirmed the
results of Thieben et al., who reported that 31.6% of a cohort
of 152 PoTS patients suffered from sleep disturbances and even
48.0% that complained about fatigue (4). Bagai et al. reported
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51% PoTS patients (n= 44) with excessive daytime sleepiness (9).
One could expect a coherency of diminished subjective sleep qual-
ity, increased daytime sleepiness, and diminished sleep efficiency.
In our study, PSG parameters showed no differences in sleep effi-
ciency or frequency of arousals between both groups. One of the
PoTS patients was diagnosed with sleep apnea and treated with
CPAP (ESS score 2) whilst two PoTS patients showed increased
PLM during night, these patients also showed ESS scores over
10, which could be due to PLMs. The significance of these findings
needs further evaluation. However, sleep architecture showed a sig-
nificantly higher proportion of sleep stage 2 in patients with PoTS.
This phenomenon could also be detected in patients with insomnia
and points out the evidence of objective primary sleep disorders
in PoTS patients. Slow wave sleep percentage was slightly higher
in control subjects (39.25 vs. 41.30%; n.s.), but not statistically
significant. There was no significant difference in the proportion
of REM sleep between the two groups. However, four of the PoTS
patients did not even reach REM sleep stage throughout the night.
Spectral analyses of HRV data during different sleep stages
(sleep stage 2, slow wave sleep, and REM) demonstrated character-
istic sleep stage-related changes in ANS activity in control subjects
(23–27). Parasympathetic activity increased with synchronization
of sleep while LF/HF ratio which presents sympathovagal balance
decreased. In REM sleep, LF/HF ratio increased, which indicates a
sympathetic dominance. Separate analyses of LF band, HF band,
and LF/HF ratio showed stage-related differences between the two
patient groups. In control subjects, LF band showed a significant
decrease from sleep stage 2 to slow wave sleep, which could not be
detected in patients with PoTS. Furthermore in control subjects,
HF band showed a significant decrease from sleep stage 2 to slow
wave sleep and also from slow wave sleep to REM sleep. In PoTS
patients, HF band did not vary to the same extent. Median values of
the LF/HF ratio appeared to be consistently lower in PoTS patients.
With reference to LF/HF ratio, there was a significant increase from
sleep stage 2 to REM sleep and also from slow wave sleep to REM
sleep in control subjects. In PoTS patients, no significant stage-
related change in LF/HF ratio was seen. This phenomenon leads
to the conclusion that PoTS patients have an altered HRV during
night. In some PoTS patients, cardiac dysautonomic neuropathy
with reduced myocardial 123I-meta-iodobenzylguanidine uptake
was reported, which could also be a reason for diminished HRV
in different sleep stages (28, 29). An altered state dependent mod-
ulation of HRV may not only derive from cardiac dysautonomic
neuropathy, but also from a hyperadrenergic state (5).
As a limitation of the present study, the results of sleep
efficiency, sleep architecture, and arousal frequency should be
interpreted carefully since they could be affected by a “first night
effect” (30) due to the lack of an adaption night. However, accord-
ing to Israel et al., HRV is not affected by the “first night effect”
(31). With regard to the measurement of arousals, the present
study is limited by the consideration of changes in EEG pat-
terns only. If there are other sorts of arousals, which would only
affect cardiorespiratory parameters, like autonomic arousals pre-
sumably do, they would have not been evaluated by the present
trial. In fact, there is no proper definition to classify autonomic
arousals to this date. Future studies into this field could evalu-
ate autonomic arousal, since it may affect sleep architecture and
cause sleep disturbances in PoTS patients. Very recently Sasai et al.
found that an elevation of sympathetic nervous system activ-
ity and mean frequency fluctuation in an HF band can occur
several seconds before the period of PLMs. Therefore, specific
analysis of HRV in PLM period could be an interesting aspect
for future research. Our results are probably unaffected by auto-
nomic fluctuation prior to PLMs, since analyzed HRV periods
were copied to the ECG at least 10 min before or after an arousal
occurred. The presence of PLMS or OSA(S) (AHI 10.5/h) may
be a confounding factor for analysis. Another theory, which is
not evaluated in the present study, is the coherency of sleep dif-
ficulties and anxiety in PoTS patients. It is conceivable that this
could be an alternative cause of sleeping disorders, as a connec-
tion between anxiety disorders and sleep disturbances in other
patients as already reported by Soehner et al. (32). On the other
hand, in a previous study, it has been found that an increase of
propensity to anxiety disorders existed in PoTS only when ques-
tionnaires were used that included autonomic items (33). For
further research, PoTS patients could be divided into two groups
via PSQI and ESS scores, thus autonomic parameters in PoTS
patients could be compared with and without subjective sleeping
disorder/sleepiness. From a statistical point of view, a large num-
ber of variables were tested without controlling for type I error
(e.g., Bonferroni approach). The study is also restricted by per-
forming it only in the Helios Klinikum Wuppertal and results may
not be transmitted to other settings due to, e.g., other ethnicities
in other clinical setting.
CONCLUSION
Postural tachycardia syndrome patients had a subjective dimin-
ished sleep quality, reached higher levels of daytime sleepiness, and
showed a diminished proportion of sleep stage 2. Since all these
symptoms can be also seen in patients with insomnia, PoTS should
be included as a potential differential diagnosis of insomniacs.
PoTS patients showed normal sleep when objectively evaluated by
PSG. Furthermore, analyses of HRV during different sleep stages
showed altered HRV during different sleep stages in PoTS. Sleep
physicians should be aware of sleep disturbances associated with
this form of orthostatic intolerance.
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